# US 2022/0003767 A1 · Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0003767 A1
- Document ID: US20220003767A1
- Status: Published application
- Kind: A1
- Application number: 17/289,900
- Filed: 2019-10-30
- Published: 2022-01-06
- Earliest claimed: 2019-10-30
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Nicole ROBB; Achillefs KAPANIDIS; Jonathan TAYLOR
- Web page: https://patentgrep.com/patent/US20220003767A1

## CPC

- G01N 33/582: {with fluorescent label}
- B32B 3/266: {characterised by an apertured layer, the apertures going through the whole thickness of the layer, e.g. expanded metal, perforated layer, slit layer regular cells B32B3/12}
- B32B 5/022: {Non-woven fabric}
- B32B 5/08: the fibres or filaments of a layer being of different substances {, e.g. conjugate fibres, mixture of different fibres}
- B32B 5/18: characterised by features of a layer {of} foamed material
- B32B 5/245: {another layer next to it being a foam layer}
- B32B 5/26: another layer {next to it} also being fibrous or filamentary {(relative arrangement of fibres or filaments of different layers B32B5/12)}
- B32B 5/32: {at least two} layers being foamed {and next to each other}
- B32B 7/08: by mechanical means
- B32B 25/042: {of natural rubber or synthetic rubber}
- B32B 25/08: of synthetic resin
- B32B 25/10: next to a fibrous or filamentary layer
- B32B 25/16: comprising polydienes {homopolymers} or poly-halodienes {homopolymers (B32B25/12 takes precedence)}
- B32B 25/18: comprising butyl or halobutyl rubber
- B32B 27/08: of synthetic resin
- B32B 27/12: next to a fibrous or filamentary layer
- B32B 27/308: {comprising acrylic (co)polymers}
- B32B 27/36: comprising polyesters
- B32B 27/40: comprising polyurethanes
- B60J 7/1226: {Soft tops for convertible vehicles}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/68: involving nucleic acids
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/56983: {Viruses}
- G01N 33/586: {Liposomes, microcapsules or cells}
- B32B 2250/05: 5 or more layers
- B32B 2262/02: Synthetic macromolecular fibres
- B32B 2262/0246: Acrylic resin fibres
- B32B 2262/0253: Polyolefin fibres
- B32B 2262/0261: Polyamide fibres
- B32B 2262/0276: Polyester fibres
- B32B 2262/0292: Polyurethane fibres
- B32B 2262/062: Cellulose fibres, e.g. cotton
- B32B 2262/14: Mixture of at least two fibres made of different materials
- B32B 2266/0242: Acrylic resin
- B32B 2266/0278: Polyurethane
- B32B 2266/06: Open cell foam
- B32B 2307/102: Insulating
- B32B 2307/718: Weight, e.g. weight per square meter
- B32B 2307/732: Dimensional properties
- B32B 2605/003: Interior finishings
- C12N 2310/3517: Marker; Tag
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16131: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16221: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16232: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2760/16251: Methods of production or purification of viral material
- C12Q 2525/00: Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q 2563/107: fluorescence
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B32B: LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B60J: WINDOWS, WINDSCREENS, NON-FIXED ROOFS, DOORS, OR SIMILAR DEVICES FOR VEHICLES; REMOVABLE EXTERNAL PROTECTIVE COVERINGS SPECIALLY ADAPTED FOR VEHICLES (fastening, suspending, closing, or opening of such devices E05)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Provided herein is a method of functionalizing a particle, as well as methods of optically tracking a particle, isolating enveloped viral particles from a sample, quantifying enveloped virus particles in a sample and assessing enveloped viral aggregation in a sample. Kits are also provided. The particle is typically a viral particle.

## Claims

### Claim 1

A method of functionalizing a particle with a negatively charged polymer; the particle having a negatively charged surface and a lipid coating; wherein the method comprises contacting said particle with (i) a polyvalent cation and (ii) said polymer; such that the polymer binds to the particle thereby functionalizing the particle.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the particle is a nanoparticle.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or claim 2 wherein the particle is an enveloped virus particle.

### Claim 4 (depends on 3)

A method according to claim 3 wherein the virus is selected from herpesviridae, poxviridae, pneumoviridae, hepadnaviridae, flaviviridae, togaviridae, coronaviridae, hepatitis D virus, orthomyxoviridae, paramyxoviridae, rhabdoviridae, bunyaviridae, filoviridae, baculoviridae and retroviridae;
wherein preferably the virus is an influenza virus.

### Claim 5 (depends on 3, 4)

A method according to claim 3 or claim 4 wherein the virus is present in a biological fluid, wherein preferably the biological fluid is allantoic fluid or is a cell culture medium.

### Claim 6

A method according to any one of the preceding claims wherein the polyvalent cation is a divalent metal cation; wherein preferably the polyvalent cation is Ca2+; optionally wherein the Ca2+ is provided as CaCl2).

### Claim 7

A method according to any one of the preceding claims wherein the negatively charged polymer is a polynucleotide, a polypeptide, a polysaccharide or a negatively charged polyether;
wherein preferably the negatively charged polymer is a polynucleotide, preferably an oligonucleotide.

### Claim 8

A method according to any one of the preceding claims wherein the negatively charged polymer comprises a detectable label and/or an immobilisation tag and/or one or more reactive functional groups; wherein preferably
the detectable label is an optically detectable label, preferably a fluorescent or chemiluminescent label; or
the immobilisation tag is an affinity tag, preferably a biotin tag.

### Claim 9

A method according to any one of the preceding claims, wherein the particle is an enveloped virus particle; the polyvalent cation is Ca2+ and the negatively charged polymer is a polynucleotide;
said method comprising contacting in solution at least about 102 PFU/mL viral particles with at least about 10 mM Ca2+ and at least about 1 nM polynucleotide.

### Claim 10

A method according to any one of the preceding claims, comprising contacting the particle with the polyvalent cation and the negatively charged polymer for less than about 30 minutes, preferably for less than about 15 minutes.

### Claim 11

A method according to any one of the preceding claims, wherein the particle is an enveloped virus particle; the method further comprising the step of binding the functionalized virus particle to a host cell.

### Claim 12

A method according to any one of the preceding claims further comprising releasing the polymer from the functionalized particle by contacting the functionalized particle with a chelating agent for the polyvalent cation.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A functionalized particle, comprising:
a particle having a negatively charged surface and a lipid coating;
a negatively charged polymer; and
a polyvalent cation which binds the polymer to the particle;
optionally wherein the functionalized particle is obtainable by a method as defined in any one of claims 1 to 10;
wherein preferably:
the particle is as defined in any one of claims 2 to 5; and/or
the polyvalent cation is as defined in claim 6; and/or
the negatively charged polymer is as defined in claim 7 or claim 8.

### Claim 14 (depends on 13)

A composition comprising a functionalized particle as defined in claim 13 and a carrier medium.

### Claim 15 (depends on 13)

A method of binding a functionalized virus particle to a host cell, which method comprises binding to a host cell a functionalized particle as defined in claim 13; wherein the particle is an enveloped virus particle.

### Claim 16 (depends on 13)

A method of releasing a polymer from a functionalized particle as defined in claim 13, which method comprises contacting the functionalized particle with a chelating agent for the polyvalent cation.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of optically tracking a particle having a negatively charged surface and a lipid coating; the method comprising:
a) functionalizing the particle with a negatively charged polymer by a method as defined in any one of claims 1 to 12, wherein the negatively charged polymer comprises an optically detectable label; and
b) optically tracking the optically detectable label thereby tracking the particle; wherein preferably the particle is an enveloped viral particle.

### Claim 18 (depends on 13)

A method of tracking a particle as defined in claim 13, wherein the negatively charged polymer comprises an optically detectable label, and the method comprises optically tracking said optically detectable label.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of functionalizing the surface of a particle having a negatively charged surface and a lipid coating; the method comprising functionalizing the particle with a negatively charged polymer in a method according to any one of claims 1 to 12; wherein the negatively charged polymer comprises one or more reactive functional groups; such that the polymer binds to the surface of the particle thereby functionalizing the surface of the particle;
wherein preferably the particle is an enveloped viral particle.

### Claim 20 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of isolating enveloped viral particles from a sample, comprising:
a) functionalizing the enveloped viral particles in the sample with a negatively charged polymer according to any one of claims 3 to 12; wherein the negatively charged polymer comprises an immobilization tag;
b) contacting the immobilisation tag with a substrate therefor such that the immobilisation tag binds to the substrate;
c) isolating the substrate from the sample; and
d) optionally releasing the viral particles from the substrate.

### Claim 21 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of quantifying enveloped virus particles in a sample, comprising:
a) functionalizing the enveloped viral particles in the sample with a negatively charged polymer according to any one of claims 3 to 12; wherein the negatively charged polymer comprises a detectable label;
b) detecting the detectable label; and
c) determining the number or concentration of detectable labels in the sample thereby quantifying the number or concentration of labelled viral particles in the sample.

### Claim 22 (depends on 21)

A method according to claim 21 wherein the detectable label is a fluorescent label and wherein detecting the fluorescent label involves passing the labelled viral particles in the sample through a fluidics system having a detection zone and comprising an optical detector, photo-illuminating the detection zone and thereby detecting fluorescence of the labelled viral particles in the confocal volume.

### Claim 23 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

A method of assessing enveloped viral aggregation in a sample, comprising:
a) functionalizing the enveloped viral particles in the sample with a negatively charged polymer according to any one of claims 3 to 12; wherein the negatively charged polymer comprises an optically detectable label; wherein the individual viruses in the population have a known size;
b) optically tracking motion of the labelled viral particles;
c) determining an average diffusion coefficient for the labelled viral particles in the sample and thereby obtaining an estimate of the particulate size of the labelled viral particles;
d) comparing the known size of the viruses in the population with the estimated particulate size of the labelled viral particles and thereby assessing the extent of viral aggregation in the sample.

### Claim 24 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method according to any one of claims 15 to 23 wherein:
the enveloped viral particles comprise a virus as defined in claim 4 or claim 5; and/or
the polyvalent cation is as defined in claim 6; and/or
the negatively charged polymer is as defined in claim 7 or claim 8; and/or
the particle is functionalized as defined in claim 9 or claim 10; and/or
the method further comprises the steps set out in any one of claim 11 or 12.

### Claim 25

A kit comprising:
(i) a particle having a negatively charged surface and a lipid coating;
(ii) a negatively charged polymer; and
(iii) a polyvalent cation for binding the polymer to the particle.
